Related: Crazy-expensive weight loss drugs may soon see a major change In other news, The Biden Administration is set to introduce a change that could impact more than 7 million people covered by Medicare and Medicaid.

The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield your kidneys from harm. In the largest study to date on the effects of the drugs on the kidneys,

Medicare currently only covers these drugs for people who are diagnosed with diabetes or cardiovascular disease with obesity, or for people who are overweight, according to the official, who added that while some state Medicaid programs cover the GLP-1 ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and Medicaid. However, the move would have to be approved by the new Trump administration.

President Joe Biden’s proposal to have GLP-1 weight-loss drugs such as Wegovy, Ozempic, Zepbound and Mounjaro covered by Medicare and Medicaid would help tackle the public-health crisis of obesity, but it would raise the costs for the government programs by billions of dollars per year.

The Biden administration called for Medicare and Medicaid to cover popular drugs that help people lose weight but are not affordable for many Americans who might benefit from them. NBC News' Stephanie Gosk reports.